
Peripheral Artery Disease (PAD): Competitive Landscape
Description
Peripheral Artery Disease (PAD): Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics.
- More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD.
- The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others.
- The PAD pipeline mainly includes receptor agonists, followed by biological factor activators and enzyme inhibitors.
- The majority of Phase III trials were backed by commercial sponsors, academic sponsors mostly conducted Phase II trials.
- In deals involving companies developing PAD assets that occurred during past 10 years, Partnerships and acquisitions were the most prevalent deal type in North America, acquisitions dominated in Europe and Asia-Pacific.
GlobalData’s PAD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the PAD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
77 Pages
- Report Scope
- Key Findings
- Disease Etiology (1/2)
- Epidemiology Overview - Diagnosed Prevalent Cases of PAD in 2023 and 2024
- Treatment Guidelines
- Treatment Algorithm - Choice of Antithrombotic Therapy in PAD
- Marketed Drugs - Leading Marketed Drugs in PAD
- Marketed Drugs - Overview by Mechanism of Action
- Marketed Drugs - Overview by Route of Administration
- Marketed Drugs - Overview by Molecule Type
- Marketed Drug Profile - Bayer's Xarelto
- Marketed Drug Profile - Merck's Zontivity
- Marketed Drug Profile - AnGes's Collategene
- Marketed Drug Profile - Artgen Biotech's Neovasculgen
- Marketed Drug Profile - Sihuan Pharmaceutical's Anjieli
- Marketed Drug Profile - Libbs Farmaceutica's Cebralat
- Marketed Drugs - Annual Cost of Therapy
- Marketed Drugs - Time to Pricing and Reimbursement for Xarelto
- Pipeline Drugs Overview - Late-Stage Pipeline Drugs in PAD
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by Mechanism of Action
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in PAD
- Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Cardiovascular and PAD
- Clinical Trials in PAD - Historical Overview
- Clinical Trials in PAD - Overview by Phase
- Clinical Trials in PAD - Overview by Status
- Clinical Trials in PAD - Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in PAD - Trials with a Virtual Component
- Clinical Trials in PAD - Geographic Overview
- Clinical Trials in PAD - Single-Country and Multinational Trials by Region
- Clinical Trials in PAD - Top Sponsors with Breakdown by Phase
- Clinical Trials in PAD - Top Sponsors with Breakdown by Status
- Clinical Trials in PAD - Overview by Endpoint Status
- Clinical Trials in PAD - Overview by Race and Ethnicity
- Clinical Trials in PAD - Enrollment Data
- Clinical Trials in PAD - Overview of Sites by Geography
- Clinical Trials in PAD - Top 20 Countries for Trial Sites
- Clinical Trials in PAD - Top 20 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for PAD
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in PAD by Region
- Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in PAD
- Commercial Assessment - Key Market Players in PAD
- Future Market Catalysts - Upcoming Market Catalysts in PAD
- Methodology - Sales Forecasts
- Methodology - Pricing and Reimbursement (1/2)
- Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.